1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis NIH BRAIN Initiative aims to advance fundamental understanding of human brain function and translate this knowledge into impactful clinical technologies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: This is a highlighted topic for investigator-initiated applications. Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants. Confirm the full requirements in the official notice before applying.
Applications for BRAIN Initiative: Advancing Human Neuroscience and Precision Molecular Therapies for Transformative Treatments are due January 22, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
BRAIN Initiative: Advancing Human Neuroscience and Precision Molecular Therapies for Transformative Treatments is funded by National Institute of Neurological Disorders and Stroke (NINDS) (and other NIH ICOs). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H launched SPECTRA on September 17, 2026 under solicitation ARPA-H-SOL-26-163 — four technical areas with separate Solution Summary deadlines on October 18, December 2, and January 18. The enabling-technologies area closes first, five weeks after launch. Here is why the sequencing matters and how to read each TA.
Read article